 Can-Fite BioPharma Ltd NYSE: CANF announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson experienced a Complete Response CR. Under treatment with Namodenoson, the patient has now survived five years. 